Literature DB >> 17533017

Percutaneous transcatheter hepatic artery embolization for liver cysts in autosomal dominant polycystic kidney disease.

Ryoji Takei1, Yoshifumi Ubara, Junichi Hoshino, Yasushi Higa, Tatsuya Suwabe, Yoko Sogawa, Kazufumi Nomura, Shohei Nakanishi, Naoki Sawa, Hideyuki Katori, Fumi Takemoto, Shigeko Hara, Kenmei Takaichi.   

Abstract

BACKGROUND: We have achieved renal contraction therapy in patients with autosomal dominant polycystic kidney disease (ADPKD) by means of renal transcatheter arterial embolization (TAE) using intravascular coils, decreasing renal size and improving quality of life in almost all patients. We presently perform hepatic TAE in patients with intractable symptomatic polycystic liver. STUDY
DESIGN: Uncontrolled trial. SETTING & PARTICIPANTS: 30 patients with ADPKD referred for arteriography to an academic medical center. 22 patients had kidney failure treated by means of dialysis. INTERVENTION: We embolized arteries supplying hepatic segments replaced by cysts that were associated with well-developed hepatic arteries, but obstructed intrahepatic portal veins. OUTCOMES & MEASUREMENTS: Various volumes before and after TAE were compared by using computed tomography and National Institutes of Health Image software in 30 patients with follow-up computed tomography 18 to 37 months after therapy.
RESULTS: Total liver volume and total intrahepatic cyst volume decreased from 7,882 +/- 2,916 and 6,677 +/- 2,978 to 6,041 +/- 2,282 and 4,625 +/- 2,299 cm(3), respectively (P < 0.0001 for both). Fractions of remaining (FR) total liver volume and FR of intrahepatic cyst volume were 78.8% +/- 17.6% and 70.4% +/- 20.9%, respectively. Hepatic parenchyma increased from 1,205 +/- 250 to 1,406 +/- 277 cm(3) (P = 0.0004). In 29 of 30 patients, both total liver volume and intrahepatic cyst volume decreased; in 1 patient, total liver volume increased from 5,755 to 7,069 cm(3), whereas cysts enlarged from 4,500 to 5,531 cm(3). No serious complications were experienced. In 24 patients, the post-TAE course was favorable. TAE failed to benefit 6 patients because of unrelated hepatic infection, peritonitis, hepatic failure, acute leukemia, or pelvic fracture. LIMITATIONS: Absence of a control group.
CONCLUSIONS: TAE may be an option for patients with ADPKD with symptomatic polycystic liver who are not candidates for surgical treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533017     DOI: 10.1053/j.ajkd.2007.03.018

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  23 in total

Review 1.  Medical therapy for polycystic liver disease.

Authors:  S Khan; A Dennison; G Garcea
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

Review 2.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 3.  Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases.

Authors:  Bassam Abu-Wasel; Caolan Walsh; Valerie Keough; Michele Molinari
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

4.  Umbilical hernia in autosomal dominant polycystic kidney disease.

Authors:  Yoshinari Hattori; Junichi Hoshino; Tatsuya Suwabe; Keiichi Sumida; Koki Mise; Noriko Hayami; Naoki Sawa; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Clin Exp Nephrol       Date:  2014-01-10       Impact factor: 2.801

Review 5.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

Review 6.  Isolated polycystic liver disease.

Authors:  Qi Qian
Journal:  Adv Chronic Kidney Dis       Date:  2010-03       Impact factor: 3.620

7.  Symptom relief and quality of life after combined partial hepatectomy and cyst fenestration in highly symptomatic polycystic liver disease.

Authors:  Lucas H P Bernts; Myrte K Neijenhuis; Marie E Edwards; Jeff A Sloan; Jenna Fischer; Rory L Smoot; David M Nagorney; Joost P H Drenth; Marie C Hogan
Journal:  Surgery       Date:  2020-05-08       Impact factor: 3.982

Review 8.  Diagnosis and management of polycystic liver disease.

Authors:  Tom J G Gevers; Joost P H Drenth
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

9.  Survival after arterial embolization therapy in patients with polycystic kidney and liver disease.

Authors:  Junichi Hoshino; Tatsuya Suwabe; Noriko Hayami; Keiichi Sumida; Koki Mise; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Masayuki Yamanouchi; Eiko Hasegawa; Naoki Sawa; Ryoji Takei; Kenmei Takaichi; Yoshifumi Ubara
Journal:  J Nephrol       Date:  2014-09-18       Impact factor: 3.902

10.  Transcatheter arterial embolization therapy for a massive polycystic liver in autosomal dominant polycystic kidney disease patients.

Authors:  Hayne Cho Park; Chi Weon Kim; Han Ro; Ju-Young Moon; Kook-Hwan Oh; Yonsu Kim; Jung Sang Lee; Yong Hu Yin; Hwan Jun Jae; Jin Wook Chung; Curie Ahn; Young-Hwan Hwang
Journal:  J Korean Med Sci       Date:  2009-02-28       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.